Search
CCR-23-3029_OF
https://kcp.utsw.edu/wp-content/uploads/2024/05/arohif.pdf
CLINICAL CANCER RESEARCH | CLINICAL TRIALS: TARGETED THERAPY A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2a in Patients with Advanced Clear Cell Renal Cell Carcinoma James Brugarolas1, Gregory Obara2, Kathryn E. Beckermann3, Brian Rini3, Elaine T. Lam4, James Hamilton5, Thomas Schluep5, Min Yi5, So Wong5, Zhongping Lily Mao5, Erick Gamelin6, and Nizar M. Tannir7 ABSTRACT ◥ Purpose: ARO-HIF2 is an siRNA drug designed to selectively target hypoxia
Foundation Giving - UT Southwestern Medical Center
https://engage.utsouthwestern.edu/foundation-giving
The Office of Development & Alumni Relations Foundation Giving team works to promote UT Southwestern’s engagement with charitable foundations in order to address the most critical priorities of the institution and the needs of the community
The Brain and Computers - UT Southwestern Medical Center
https://engage.utsouthwestern.edu/events/2024/the-brain-and-computers
Join The Vanguard as we explore advances at the intersection of neuroscience and technology.
ACEP24 Alumni Reception - UT Southwestern Medical Center
https://engage.utsouthwestern.edu/events/2024/acep24-alumni-reception
Join UT Southwestern Medical Center for a reception during the American College of Emergency Physicians 2024 Scientific Assembly.
The March of Science - UT Southwestern Medical Center
https://engage.utsouthwestern.edu/events/2023/the-march-of-science
Join The Vanguard as we explore the latest advances in using biology and engineering to drive innovation in medicine.
Meet the fourth-quarter Strauss Award winners - CT Plus - UT Southwestern
https://www.utsouthwestern.edu/ctplus/stories/2023/strauss-award-q4.html
The 2022 fourth-quarter award honorees were celebrated during a virtual event on Feb. 24, hosted by John Warner, M.D., Executive Vice President for Health System Affairs and Health System CEO.
Pubs1992.pdf
https://www.utsouthwestern.edu/media/files/1700/Pubs1992.pdf
1992 Publications Total of 30 1. Cholesterol-lowering drugs as cardioprotective agents. Grundy SM. Am J Cardiol. 1992 Dec 21;70(21):27I-32I. Review.PMID: 1471602 [PubMed - indexed for MEDLINE] Related citations 2. Comparison of effects of lauric acid and palmitic acid on plasma lipids and lipoproteins. Denke MA, Grundy SM. Am J Clin Nutr. 1992 Nov;56(5):895-8.PMID: 1415008 [PubMed
Pubs1996.pdf
https://www.utsouthwestern.edu/media/files/1700/Pubs1996.pdf
1996 Publications Total of 28 1. American College of Physicians guidelines on cholesterol screening. Grundy SM, Pearson TA. Ann Intern Med. 1996 Dec 15;125(12):1008; author reply 1009-10. No abstract available. PMID: 8967693 [PubMed - indexed for MEDLINE]Free Article Related citations 2. Relationship of generalized and regional adiposity to insulin sensitivity in men with NIDDM
Pubs2007.pdf
https://www.utsouthwestern.edu/media/files/1700/Pubs2007.pdf
2007 Publications Total of 50 1. Effects of torcetrapib in patients at high risk for coronary events.Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators. N Engl J Med. 2007 Nov 22;357(21):2109-22. Epub 2007 Nov 5.PMID: 17984165 [PubMed - indexed for MEDLINE]Related articlesFree article 2. Cardiovascular and metabolic risk
Pubs1999.pdf
https://www.utsouthwestern.edu/media/files/1700/Pubs1999.pdf
1999 Publications Total of 31 1. Physical activity in the prevention and treatment of obesity and its comorbidities. Grundy SM, Blackburn G, Higgins M, Lauer R, Perri MG, Ryan D. Med Sci Sports Exerc. 1999 Nov;31(11 Suppl):S502-8. Review. No abstract available. PMID: 10593519 [PubMed - indexed for MEDLINE]Related citations 2. Physical activity in the prevention and treatment of obesity